CXC Chemokine Receptor 4 (CXCR4) Targeted Gold Nanoparticles Potently Enhance Radiotherapy Outcomes in Breast Cancer

Overview

Journal Nanoscale

Specialty Biotechnology

Date 2021 Nov 10

PMID 34757363

Citations 7

Authors

Shanta Bhattarai

Yuri Mackeyev

Bhanu P Venkatesulu

Sunil Krishnan

Pankaj K Singh

Affiliations

Soon will be listed here.

Abstract

CXC chemokine receptor 4 (CXCR4) is overexpressed on most breast cancer cell surfaces including triple negative breast cancer (TNBC) which lacks traditional receptor overexpression. We targeted gold nanoparticles (GNPs) to this receptor conjugation to anti-CXCR4 antibody (cGNPs). Irradiation of cells treated with cGNPs compared to PEGylated GNPs (pGNPs) resulted in more prominent radiosensitization of MDA-MB-231 cells with abundant CXCR4 overexpression than HTB-123 cells with moderate and MCF-7 cells with minimal CXCR4 overexpression. Overexpression of CXCR4 facilitated improved cellular internalization of cGNPs and irradiation of internalized cGNPs resulted in more unrepaired DNA double strand breaks and increased the production of oxygen free radicals compared to irradiation with non-internalized pGNPs. In a murine TNBC xenograft model, CXCR4 targeting potently increased tumor regrowth delay following radiation compared to radiation in the presence of pGNPs or vehicle alone. CXCR4 targeted GNPs enhance the efficacy of TNBC radiotherapy by increasing oxidative stress and DNA damage.

Citing Articles

RBM15 recruits myeloid-derived suppressor cells via the m6A-IGF2BP3/CBR3-AS1/miR-409-3p/CXCL1 axis, facilitating radioresistance in non-small-cell lung cancer.

Hu S, Zhan N, Li J, Wang L, Liu Y, Jin K J Transl Med. 2025; 23(1):191.

PMID: 39962467 PMC: 11831794. DOI: 10.1186/s12967-025-06205-y.

Employing antagonistic C-X-C motif chemokine receptor 4 antagonistic peptide functionalized NaGdF nanodots for magnetic resonance imaging-guided biotherapy of breast cancer.

Li X, Bao Y, Li Z, Teng P, Ma L, Zhang H Sci Rep. 2024; 14(1):15764.

PMID: 38982161 PMC: 11233619. DOI: 10.1038/s41598-024-66645-2.

Diagnosis and treatment status of inoperable locally advanced breast cancer and the application value of inorganic nanomaterials.

Wu L, He C, Zhao T, Li T, Xu H, Wen J J Nanobiotechnology. 2024; 22(1):366.

PMID: 38918821 PMC: 11197354. DOI: 10.1186/s12951-024-02644-9.

Application of High-Z Nanoparticles to Enhance Current Radiotherapy Treatment.

Jackson N, Cecchi D, Beckham W, Chithrani D Molecules. 2024; 29(11).

PMID: 38893315 PMC: 11173748. DOI: 10.3390/molecules29112438.

Functionalized Hybrid Iron Oxide-Gold Nanoparticles Targeting Membrane Hsp70 Radiosensitize Triple-Negative Breast Cancer Cells by ROS-Mediated Apoptosis.

Wu Z, Stangl S, Hernandez-Schnelzer A, Wang F, Kafshgari M, Bashiri Dezfouli A Cancers (Basel). 2023; 15(4).

PMID: 36831510 PMC: 9954378. DOI: 10.3390/cancers15041167.

References

Luga V, Zhang L, Viloria-Petit A, Ogunjimi A, Inanlou M, Chiu E . Exosomes mediate stromal mobilization of autocrine Wnt-PCP signaling in breast cancer cell migration. Cell. 2012; 151(7):1542-56. DOI: 10.1016/j.cell.2012.11.024. View

Darby S, McGale P, Correa C, Taylor C, Arriagada R, Clarke M . Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet. 2011; 378(9804):1707-16. PMC: 3254252. DOI: 10.1016/S0140-6736(11)61629-2. View

Snyder S, Sobocinski P . An improved 2,4,6-trinitrobenzenesulfonic acid method for the determination of amines. Anal Biochem. 1975; 64(1):284-8. DOI: 10.1016/0003-2697(75)90431-5. View

Zhao H, Guo L, Zhao H, Zhao J, Weng H, Zhao B . CXCR4 over-expression and survival in cancer: a system review and meta-analysis. Oncotarget. 2015; 6(7):5022-40. PMC: 4467131. DOI: 10.18632/oncotarget.3217. View

Guo P, You J, Yang J, Moses M, Auguste D . Using breast cancer cell CXCR4 surface expression to predict liposome binding and cytotoxicity. Biomaterials. 2012; 33(32):8104-10. PMC: 3476061. DOI: 10.1016/j.biomaterials.2012.07.043. View

Wang R, Zhi X, Yao S, Zhang Y . LFC131 peptide-conjugated polymeric nanoparticles for the effective delivery of docetaxel in CXCR4 overexpressed lung cancer cells. Colloids Surf B Biointerfaces. 2015; 133:43-50. DOI: 10.1016/j.colsurfb.2015.05.030. View

Lee J, Chatterjee D, Lee M, Krishnan S . Gold nanoparticles in breast cancer treatment: promise and potential pitfalls. Cancer Lett. 2014; 347(1):46-53. PMC: 4142062. DOI: 10.1016/j.canlet.2014.02.006. View

Chauhan V, Martin J, Liu H, Lacorre D, Jain S, Kozin S . Angiotensin inhibition enhances drug delivery and potentiates chemotherapy by decompressing tumour blood vessels. Nat Commun. 2013; 4:2516. PMC: 3806395. DOI: 10.1038/ncomms3516. View

Singh P, Pandit S, Mokkapati V, Garg A, Ravikumar V, Mijakovic I . Gold Nanoparticles in Diagnostics and Therapeutics for Human Cancer. Int J Mol Sci. 2018; 19(7). PMC: 6073740. DOI: 10.3390/ijms19071979. View

10.

Chen I, Chauhan V, Posada J, Ng M, Wu M, Adstamongkonkul P . Blocking CXCR4 alleviates desmoplasia, increases T-lymphocyte infiltration, and improves immunotherapy in metastatic breast cancer. Proc Natl Acad Sci U S A. 2019; 116(10):4558-4566. PMC: 6410779. DOI: 10.1073/pnas.1815515116. View

11.

Chittasupho C, Lirdprapamongkol K, Kewsuwan P, Sarisuta N . Targeted delivery of doxorubicin to A549 lung cancer cells by CXCR4 antagonist conjugated PLGA nanoparticles. Eur J Pharm Biopharm. 2014; 88(2):529-38. DOI: 10.1016/j.ejpb.2014.06.020. View

12.

Mukherjee D, Zhao J . The Role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res. 2013; 3(1):46-57. PMC: 3555200. View

13.

Shima H, Yamada A, Ishikawa T, Endo I . Are breast cancer stem cells the key to resolving clinical issues in breast cancer therapy?. Gland Surg. 2017; 6(1):82-88. PMC: 5293654. DOI: 10.21037/gs.2016.08.03. View

14.

Kucia M, Reca R, Miekus K, Wanzeck J, Wojakowski W, Janowska-Wieczorek A . Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: pivotal role of the SDF-1-CXCR4 axis. Stem Cells. 2005; 23(7):879-94. DOI: 10.1634/stemcells.2004-0342. View

15.

Paszek M, Zahir N, Johnson K, Lakins J, Rozenberg G, Gefen A . Tensional homeostasis and the malignant phenotype. Cancer Cell. 2005; 8(3):241-54. DOI: 10.1016/j.ccr.2005.08.010. View

16.

Oskarsson T, Acharyya S, Zhang X, Vanharanta S, Tavazoie S, Morris P . Breast cancer cells produce tenascin C as a metastatic niche component to colonize the lungs. Nat Med. 2011; 17(7):867-74. PMC: 4020577. DOI: 10.1038/nm.2379. View

17.

Chen G, Chen S, Wang X, Ding X, Ding J, Meng L . Inhibition of chemokine (CXC motif) ligand 12/chemokine (CXC motif) receptor 4 axis (CXCL12/CXCR4)-mediated cell migration by targeting mammalian target of rapamycin (mTOR) pathway in human gastric carcinoma cells. J Biol Chem. 2012; 287(15):12132-41. PMC: 3320958. DOI: 10.1074/jbc.M111.302299. View

18.

Howlader N, Cronin K, Kurian A, Andridge R . Differences in Breast Cancer Survival by Molecular Subtypes in the United States. Cancer Epidemiol Biomarkers Prev. 2018; 27(6):619-626. DOI: 10.1158/1055-9965.EPI-17-0627. View

19.

Dewan M, Ahmed S, Iwasaki Y, Ohba K, Toi M, Yamamoto N . Stromal cell-derived factor-1 and CXCR4 receptor interaction in tumor growth and metastasis of breast cancer. Biomed Pharmacother. 2006; 60(6):273-6. DOI: 10.1016/j.biopha.2006.06.004. View

20.

Palma D, Olson R, Harrow S, Gaede S, Louie A, Haasbeek C . Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet. 2019; 393(10185):2051-2058. DOI: 10.1016/S0140-6736(18)32487-5. View